<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229160</url>
  </required_header>
  <id_info>
    <org_study_id>2018/418/HP</org_study_id>
    <nct_id>NCT04229160</nct_id>
  </id_info>
  <brief_title>Noninvasive 3D Mapping in Persistent Atrial Fibrillation, to Describe Modifications of the Arrhythmogenic Substrate After Pulmonary Vein Isolation and Identify Potential Predicting Factors of Ablation Success</brief_title>
  <acronym>CRYOVEST</acronym>
  <official_title>Noninvasive 3D Mapping in Persistent Atrial Fibrillation, to Describe Modifications of the Arrhythmogenic Substrate After Pulmonary Vein Isolation and Identify Potential Predicting Factors of Ablation Success</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common cardiac arrhythmia in adults. It is a major cause
      of ischemic stroke and heart failure. Intravascular cardiac ablation of the left atrium by
      catheter delivery is an efficient treatment to restore sinus rhythm. AF ablation is a class
      IIa treatment for patients with symptomatic persistent AF refractory or intolerant to
      antiarrhythmic medication. There are still many debates considering the ablation strategy.
      The pulmonary veins remain the cornerstone of AF ablation therapy, even in persistent AF.
      There is a large electrical remodeling occurring in the left atrium between paroxysmal AF,
      early persistent AF and long-standing persistent AF. However, no multicentric and randomized
      study has demonstrated so far the interest of targeting other left atrial substrate, such as
      rotors or focal sources.

      Our study aims to describe with a noninvasive mapping system the arrhythmogenic substrate of
      persistent AF &gt; 6 months pre- and post-cardioversion, and after pulmonary vein isolation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of focal sources and rotors in atrial segments</measure>
    <time_frame>within 1 hour post-cardioversion procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of focal sources and rotors in atrial segments</measure>
    <time_frame>within 1 hour post-Pulmonary Vein Isolation procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Atrial Fibrillation recurrence following AF ablation procedure</measure>
    <time_frame>1 year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of success of Atrial Fibrillation induction after initial electrical cardioversion</measure>
    <time_frame>within 2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atrial Fibrillation, Persistent</condition>
  <arm_group>
    <arm_group_label>patient with persistent atrial fibrillation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>persistent atrial fibrillation is defined as lasting longer than 6 months documented by a 24h holter monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Noninvasive mapping (Cardioinsight® system)</intervention_name>
    <description>Noninvasive mapping (Cardioinsight® system) of the left atria before the Atrial fibrilation ablation procedure</description>
    <arm_group_label>patient with persistent atrial fibrillation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>long-term cardiac monitoring (LINQ system)</intervention_name>
    <description>long-term cardiac monitoring (LINQ system) is used to evaluate recurrence rate following AF ablation procedure</description>
    <arm_group_label>patient with persistent atrial fibrillation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrial Fibrillation ablation procedure</intervention_name>
    <description>Atrial Fibrillation ablation procedure is done with standard practice</description>
    <arm_group_label>patient with persistent atrial fibrillation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with documented persistent Atrial Fibrillation lasting longer than 6 months
             documented by 24h holter monitoring

          2. Age between 18 and 75 years

          3. Efficient oral anticoagulation during at least 1 month before the procedure

          4. Social security affiliation

          5. Feasible patient follow-up

          6. Patient willing to comply with study requirements and give informed consent to
             participate in this clinical study

          7. Indication for Pulmonary Vein isolation

        Exclusion Criteria:

          1. Previous atrial fibrillation ablation

          2. Previous left atrial ablation or surgery

          3. Atrial fibrillation without spontaneous RR interval &gt; 1000ms and with LVEF &lt; 35%
             (measured by TTE)

          4. Presence of a mechanical mitral valve

          5. Current intracardiac thrombus

          6. Any condition contraindicating chronic anticoagulation

          7. Uncontrolled hyperthyroidism

          8. Anteroposterior LA diameter &gt; 55 mm measured by TTE

          9. Body mass index ≥ 40 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric ANSELME, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédéric ANSELME, Pr</last_name>
    <phone>+3323288</phone>
    <phone_ext>8116</phone_ext>
    <email>frederic.anselme@chu-rouen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien BLOT</last_name>
    <phone>+3323288</phone>
    <phone_ext>8265</phone_ext>
    <email>julien.blot@chu-rouen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul MILLIEZ, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Paul MILLIEZ, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dieppe Hospital</name>
      <address>
        <city>Dieppe</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole HUCHE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carole HUCHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier du Havre</name>
      <address>
        <city>Le Havre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathanaël AUQUIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nathanaël AUQUIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric ANSELME, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Bénédicte GODIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary vein isolation</keyword>
  <keyword>cardioversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

